SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs better-than-expected quarterly results and raised full-year revenue outlook are driving attention, with traders also highlighting its growing backlog and NVIDIA research-center partnership. Bulls see evidence of commercial momentum and quantum-sector strength, while skeptics remain concerned about dilution, cash burn, and whether growth will translate into durable returns.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A Foxconn Tech Day display identifying a POET optical engine has renewed attention to the companys existing FIT collaboration, alongside the appointment of a new CFO. Traders see the visibility as validation and hope for commercial orders, while skeptics note it does not confirm new purchase orders or scaled shipments and want proof of revenue growth.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

LUNRs sharp rebound after a steep selloff has traders pointing to the dismissal of the CLPS 2 bid protest, anticipated NASA contract news, and possible short covering. Some see a recovery in space stocks, while others warn the bounce may be temporary and question whether a contract award is imminent.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Strong Q3 results and raised revenue outlook, alongside managements view that Recorlev could reach blockbuster-scale sales sooner than previously expected, are driving XERSs sharp rally. Traders are celebrating the growth story and analyst upgrades, while takeover speculation remains unconfirmed and some expect a pullback after the run.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings shares plunged after a Q3 earnings and revenue miss and a sharply reduced full-year outlook, with the company attributing much of the cut to heavy investment in its Predictions business. Traders are debating whether that spending can build a new growth engine or will weigh on profitability amid competition, while also criticizing management and the weaker guidance.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys multi-year agreement to supply engines, license propulsion technology and provide engineering support for AST SpaceMobiles planned heavy-lift rocket is driving attention. Traders largely view the deal as validation of Fireflys engine business and a boost to its outlook, while some question the stock-based payment terms and execution risks; the sharp rally has also prompted short-squeeze speculation.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins stronger-than-expected quarterly results, upbeat outlook, and expanded share-repurchase authorization have driven a sharp post-earnings rally, with traders crediting momentum in its AI-powered advertising business. Bulls see a recovery and potential for further gains, while skeptics warn the move is overextended and may draw profit-taking.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

A quarterly revenue beat, higher full-year outlook and progress in the final FAA certification stage have fueled renewed attention on JOBY, alongside updates on manufacturing and defense business. Bulls see a path toward commercialization and speculate about short covering, while skeptics stress that certification remains incomplete and cash burn and dilution risks persist.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

INFQ is rebounding alongside quantum stocks after Intels move to acquire a quantum company, which traders see as validation for the sector. The community also cites CEO Matt Kinsellas media appearance and speculates about short covering, though some view the rise as a bounce from the recent selloff rather than a company-specific catalyst.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulfs stronger-than-expected Q3 results and Google credit support for financing tied to its Anthropic data-center lease, alongside a Fluor construction agreement, have focused attention on its AI/HPC buildout. Bulls see the financing support as reducing risk, while skeptics point to sector weakness, execution and construction risks, and regulatory uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for July 7th

AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.

New Strong Sell Stocks for July  2nd

DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic...

DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing

Equity

Alpha Tau signed an agreement with Tolmar to commercialize its lead cancer therapy for prostate cancer in the United States.

DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week

An extract featuring safety and efficacy results from three studies evaluating its key therapy for pancreatic cancer will be unveiled on Thursday.

Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally

Alpha Tau Medical stock surged after interim glioblastoma data showed complete responses in two patients treated with Alpha DaRT.read more...

DRTS Stock Surges Pre-Market Even As Retail Traders Debate ‘Too Small’ Brain Cancer Trial Data 

The biotech company’s experimental treatment for recurrent glioblastoma resulted in complete responses in 2 of the first 3 patients.

Nasdaq, S&P 500 Futures Dip As Trump-Iran Tensions Lift Crude Oil Prices: Why MU, MRAM, MLTX, DRTS, ASTS Are In Focus

Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ, following last week’s resilience in tech and AI-linked names. 


DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today

Last week, Alpha Tau Medical completed enrollment in its ReStart study for recurring skin cancer.

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Still a Buy?

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's Why...

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

Neutral Sentiment

<ul class="summary-bullets"><li>Tolmar will invest $20 million in Alpha Tau at $11.99 per share, representing a 34% premium to the stock’s closing price on Tuesday.</li><li>The deal also includes up to $161.5 million in potential development, regulatory, and commercial milestones.</li><li>Tolmar will also have the option for a similar deal for bladder cancer indication in the future.</li></ul>Shares of Alpha Tau Medical (DRTS) surged more than 22% on Wednesday, after the widely tracked biotech firm announced a landmark deal with Tolmar to commercialize its lead cancer therapy for prostate cancer in the United States.Alpha Tau’s lead oncology therapy, Alpha DaRT, is being tested for the treatment of solid tumors.<h2 class="st-heading-2">Tolmar To Get Exclusive Rights For Commercialization</h2>Tolmar, a specialty pharmaceutical firm focused on urology and oncology products, will receive exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer, with an option to expand into bladder cancer.Alpha Tau will lead clinical development and remain responsible for manufacturing the therapy, while Tolmar will oversee sales and commercialization efforts.As part of the agreement, Tolmar will invest $20 million in Alpha Tau at $11.99 per share, representing a 34% premium to the stock’s closing price on Tuesday, and contribute an additional $15 million toward expanding U.S. manufacturing capacity.The deal also includes up to $161.5 million in potential development, regulatory, and commercial milestones. This takes the overall commitment to $196.5 million.<h2 class="st-heading-2">Alpha DaRT Shows Promising Results In Pancreatic Cancer Study</h2>Earlier this week, Alpha Tau reported encouraging results from a pooled analysis of three Phase I/II studies evaluating its Alpha DaRT therapy in patients with pancreatic cancer. The data showed a median overall survival of 11.2 months for metastatic patients.The therapy also demonstrated a favorable safety profile, with treatment-related adverse events reported in 36% of patients and severe Grade 3 or higher events in just 9%. No treatment-related deaths or chronic toxicities were observed, and all severe adverse events were resolved.<h2 class="st-heading-2">What Does Retail Think Of DRTS?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/DRTS">DRTS</a> on Stocktwits remained in the ‘bullish’ territory over the past 24 hours.One user said the news was “fantastic on so many levels.”<stembedurl>https://stocktwits.com/Herbgator/message/655247664</stembedurl>However, another user noted that volumes traded were relatively low.<stembedurl>https://stocktwits.com/Olivia_Strickland/message/655257581</stembedurl>Around 0.6 million shares changed hands, compared to the daily average of more than one million shares, according to Stocktwits data.DRTS shares have soared around 114% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-hits-highest-levels-in-nearly-7-months-what-s-got-investors-buzzing/cZ0j4UQRext">IREN Stock Hits Highest Levels In Nearly 7 Months – What’s Got Investors Buzzing?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Why Did DRTS Stock Surge 22% Today?

ALPHA TAU MEDICAL LTD

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$13.71
Prev Close	$13.30
Open	$13.44
Dividend Yield	0.00%
50-Day Moving Average	$14.15
Beta	0.85
Avg. Volume	461,893.55
PE Ratio	-12.79

52-Week High	$15.79
52-Week Low	$3.43
Market Capitalization	$1.23B
EPS (Annual)	-$0.529
Price to Book	27.88
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DRTS Fundamentals